CRIS Current Research Information System

BRIOLI, ANNAMARIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.037
AS - Asia 1.951
EU - Europa 1.577
AF - Africa 168
SA - Sud America 117
Continente sconosciuto - Info sul continente non disponibili 96
OC - Oceania 4
Totale 6.950
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.988
SG - Singapore 570
CN - Cina 554
VN - Vietnam 441
GB - Regno Unito 429
SE - Svezia 203
IT - Italia 200
DE - Germania 186
FR - Francia 128
HK - Hong Kong 116
IN - India 109
RU - Federazione Russa 98
BR - Brasile 85
NL - Olanda 76
IE - Irlanda 62
CI - Costa d'Avorio 56
UA - Ucraina 50
ZA - Sudafrica 46
EE - Estonia 36
TG - Togo 31
CA - Canada 25
JP - Giappone 25
CH - Svizzera 24
FI - Finlandia 22
BD - Bangladesh 21
PH - Filippine 21
KR - Corea 17
BE - Belgio 16
SC - Seychelles 14
BG - Bulgaria 13
TH - Thailandia 13
AR - Argentina 11
IR - Iran 11
PL - Polonia 9
JO - Giordania 8
NG - Nigeria 8
TR - Turchia 8
LB - Libano 7
MX - Messico 7
AT - Austria 6
EC - Ecuador 6
IQ - Iraq 6
JM - Giamaica 6
CL - Cile 5
CO - Colombia 5
ES - Italia 5
ID - Indonesia 5
TW - Taiwan 5
PK - Pakistan 4
SA - Arabia Saudita 4
AU - Australia 3
DZ - Algeria 3
GR - Grecia 3
LT - Lituania 3
VE - Venezuela 3
CR - Costa Rica 2
EG - Egitto 2
GT - Guatemala 2
HU - Ungheria 2
MA - Marocco 2
PY - Paraguay 2
TN - Tunisia 2
AE - Emirati Arabi Uniti 1
AZ - Azerbaigian 1
BB - Barbados 1
BW - Botswana 1
CZ - Repubblica Ceca 1
GD - Grenada 1
HN - Honduras 1
IL - Israele 1
KE - Kenya 1
LV - Lettonia 1
LY - Libia 1
MD - Moldavia 1
MY - Malesia 1
NC - Nuova Caledonia 1
NP - Nepal 1
OM - Oman 1
PA - Panama 1
PR - Porto Rico 1
PT - Portogallo 1
RO - Romania 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
SV - El Salvador 1
TT - Trinidad e Tobago 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 6.855
Salva come PNG Salva come JPEG
Città #
Southend 384
Singapore 375
Ashburn 339
Fairfield 334
Chandler 230
Woodbridge 184
Seattle 154
Wilmington 140
San Jose 138
Cambridge 135
Houston 129
Ann Arbor 114
Hong Kong 110
Ho Chi Minh City 98
Princeton 90
Santa Clara 89
Beijing 84
Hanoi 70
Dublin 61
Abidjan 56
New York 53
Dong Ket 52
Boardman 50
Nanjing 48
Lauterbourg 44
Council Bluffs 43
Westminster 39
Padova 38
Bologna 37
Los Angeles 36
Hefei 33
Jinan 33
Lomé 31
Shenyang 25
Bremen 23
Helsinki 22
Jacksonville 22
Saint Petersburg 21
Tokyo 21
Buffalo 18
Changsha 18
Nanchang 18
Berlin 16
Brussels 16
Turin 16
Chicago 15
Hebei 15
São Paulo 15
Da Nang 14
Haiphong 14
Redondo Beach 14
San Diego 14
Seoul 14
Hangzhou 13
Redwood City 13
Sofia 13
Bern 12
Tianjin 12
Zhengzhou 12
Dearborn 11
Paris 10
Shanghai 10
Washington 10
Frankfurt am Main 9
Guangzhou 9
Milan 9
Amman 8
Falls Church 8
Jiaxing 8
Abeokuta 7
Hyderabad 7
London 7
Medford 7
Mülheim 7
Orem 7
Rome 7
Wuhan 7
Can Tho 6
Dallas 6
Montreal 6
Ningbo 6
Norwalk 6
Phoenix 6
Toronto 6
Vienna 6
Bengaluru 5
Brooklyn 5
Charlotte 5
Falkenstein 5
Haikou 5
Lausanne 5
Modena 5
Naples 5
Taiyuan 5
Argelato 4
Baghdad 4
Bangkok 4
Catania 4
Des Moines 4
Florence 4
Totale 4.542
Salva come PNG Salva come JPEG
Nome #
Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment 272
Peripheral neuropathy induced by subcutaneous bortezomib-based induction therapy for newly diagnosed multiple myeloma. 251
Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes 238
The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD) 237
Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma 221
HIF-1α inhibition blocks the cross talk between multiple myeloma plasma cells and tumor microenvironment 206
Prognostic impact of serial measurements of serum-free light chain assay throughout the course of newly diagnosed multiple myeloma treated with bortezomib-based regimens 205
Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma 204
Successful mobilization of PBSCs predicts favorable outcomes in multiple myeloma patients treated with novel agents and autologous transplantation 202
Evaluation of bone disease in multiple myeloma patients carrying the t(4;14) chromosomal translocation. 197
Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma. 188
Thalidomide maintenance in multiple myeloma: certainties and controversies. 185
Thalidomide-dexamethasone as induction therapy before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma and renal insufficiency. 183
PET/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma 182
Long-term results of thalidomide and dexamethasone (thal-dex) as therapy of first relapse in multiple myeloma. 181
Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy following autologous hematopoietic stem-cell transplantation in patients with newly diagnosed multiple myeloma. 181
HIF 1 Alpha: A Suitable Target for Multiple Myeloma 177
High Number of Copy Number Alterations and Over-Expression of Genes Involved in the Response Mechanisms to Genotoxic Stress Both Characterize Newly Diagnosed Multiple Myeloma (MM) Patients Carrying Amplified MDM4 and/or Deleted p53 169
Gene expression analysis of newly diagnosed Multiple Myeloma (MM) patients carrying amplified MDM4 and/or deleted p5 164
Maintenance therapy in newly diagnosed multiple myeloma: current recommendations. 160
Long-term follow-up after autologous stem cell transplantation for light- and heavy-chain deposition disease. 158
High CNA level and over-expression of genes involved in response mechanisms to genotoxic stress characterize newly diagnosed Multiple Myeloma (MM) patients carrying amplified MDM4 and/or deleted TP53 156
The utility of newer imaging techniques as predictors of clinical outcomes in multiple myeloma. 150
SIRT Regulates the Molecular Interaction Between c-MYC and HIF-1α in Multiple Myeloma 147
Biologically defined risk groups can be used to define the impact of thalidomide maintenance therapy in newly diagnosed multiple myeloma. 145
Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms. 143
Therapeutic targeting of hypoxia and hypoxia-inducible factor 1 alpha in multiple myeloma 143
Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis. 141
Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcome. 140
Role of consolidation therapy in transplant eligible multiple myeloma patients. 139
Pomalidomide combinations are a safe and effective option after daratumumab failure 133
Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma. 133
The impact of intra-clonal heterogeneity on the treatment of multiple myeloma. 132
Patient with ataxia telangiectasia who developed acute myeloid leukemia. 130
The impact of long-term lenalidomide exposure on the cellular composition of bone marrow. 129
Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myeloma 128
The impact of response on bone-directed therapy in patients with multiple myeloma. 125
The Value of 18F-FDG PET/CT after Autologous Stem Cell Transplantation (ASCT) in Patients Affected by Multiple Myeloma (MM): Experience With 77 Patients 123
Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients. 109
Proteasome inhibitors: Bortezomib in multiple myeloma 94
Response and biological subtype of myeloma are independent prognostic factors and combine to define outcome after high-dose therapy. 93
Melphalan 200 mg/m2 does not increase toxicity and improves survival in comparison to reduced doses of melphalan in multiple myeloma patients 91
The road to cure in multiple myeloma: Incorporation of novel agents into autologous stem cell transplantation 65
Totale 6.950
Salva come PNG Salva come JPEG
Categoria #
all - tutte 19.718
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 19.718
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022700 0 32 45 59 77 40 16 56 26 65 126 158
2022/2023889 87 136 36 148 58 83 23 43 146 25 60 44
2023/2024267 18 34 15 28 30 80 18 4 2 22 4 12
2024/2025794 36 152 69 54 129 39 41 22 4 93 15 140
2025/20261.862 145 164 141 120 220 104 196 79 415 144 80 54
2026/2027116 43 73 0 0 0 0 0 0 0 0 0 0
Totale 6.950